What Dolofen Treats: Main Uses and Benefits

Dolofen (Diclofenac) is used to provide symptomatic relief by managing the symptom axes of pain, inflammation, and fever. It is applied in clinical settings marked by heightened symptoms across both chronic and acute conditions, generally assisting with maintaining functional stability and supporting general well-being during symptomatic phases. The medicine is utilized to relieve signs and symptoms across several key therapeutic areas.

---

This medicine is relevant for the symptomatic management of long-term conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. It is also applied in contexts requiring short-term supportive relief, such as managing acute pain and inflammation following physical trauma (sprains, strains, contusions) or after surgical procedures. Furthermore, it is relevant for managing symptoms related to episodic events, including the discomfort of Primary Dysmenorrhea and the acute pain associated with migraine attacks.

“It is used to help manage symptoms related to inflammatory or irritative states, such as stiffness, swelling, and persistent joint pain characteristic of chronic conditions.”

The symptomatic support of the medication is relevant for easing discomfort and may assist with maintaining functional stability during symptomatic periods.

---

Quick Fact: Supportive Relief for Inflammatory Symptoms (The medication is used for managing symptoms related to inflammatory or irritative states and supports the patient during difficult episodes by easing distress.)

Regulatory References

1. NIH MedlinePlus overview of Diclofenac

Who Can and Cannot Use Dolofen?

Eligibility for using Dolofen (Diclofenac) is strictly defined by regulatory authorities based on a patient's medical history, age, and physiological status. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Diclofenac, Aspirin, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including those with a history of Aspirin-sensitive asthma.

Contraindicated and Restricted Use

Population Group	Regulatory Status
Late-Stage Pregnancy (Third Trimester)	Contraindicated
Coronary Artery Bypass Graft (CABG) surgery setting	Contraindicated
Established Ischaemic Heart Disease (EU/UK Labeling)	Contraindicated
Active Gastrointestinal Ulcer/Bleeding	Contraindicated
Recent Myocardial Infarction (MI)	Avoid Use (unless benefits outweigh risk)

Age and Organ Function

Age-related use is generally established for adults, and for specific formulations, in children 12 years of age and older. Safety and efficacy are not established for most forms in younger children. Use requires caution in older adults due to an increased risk of adverse events.

Patients with advanced renal disease or hepatic impairment should use the medicine with caution, as these conditions may affect its elimination and require careful assessment.

Interactions with other medicines and products

Official regulatory documentation establishes several interaction classifications for Dolofen (Diclofenac) based on additive risks and metabolic interference.

Contraindicated Combinations and Substances

Category	Documented Restriction
Surgical Setting	Contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Allergy Risk	Contraindicated with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
Alcohol (Ethanol)	Officially documented to increase the risk of serious gastrointestinal adverse events, including stomach bleeding.

Clinically Significant Interactions

Co-administration with anticoagulants (e.g., Warfarin) or antiplatelet agents carries a documented high risk of serious bleeding. Likewise, combining with SSRIs or SNRIs is stated to increase the risk of hemorrhage. The antihypertensive effect of medicines like ACE Inhibitors and ARBs may be diminished, and this combination increases the risk of renal function deterioration, especially in elderly or renally impaired patients. The strong CYP2C9 inhibitor Voriconazole is documented to increase the plasma concentration and overall systemic exposure of Diclofenac due to inhibition of its metabolism. Additionally, for specific oral solution formulations, administration is required on an empty stomach.

Enzyme-Mediated Suppression of Inflammatory Mediators

The primary biological action of Dolofen is the competitive inhibition of cyclooxygenase ( COX) enzymes, specifically targeting COX-2, which is responsible for the rapid synthesis of prostaglandins ( PGE2) at sites of tissue damage. By blocking this enzymatic step, the drug significantly limits the creation of these lipid mediators. This mechanism modulates the inflammatory cascade by limiting mediator production. This action results in a localized decrease in vasodilatation and capillary permeability.

---

Dual Modulation of Central and Peripheral Pain Signaling

The drug's mechanism extends beyond local inflammation to modulate the nociceptive signaling system at multiple levels. In the periphery, the reduced presence of PGE2 lowers the sensitization of afferent nerve endings. Centrally, the drug engages mechanisms like the Nitric Oxide ( NO)-cGMP Pathway, which modulates the transmission of pain signals in the spinal cord and brain. This dual action on both humoral mediators and neural pathways influences the dynamics of central and peripheral nociceptive signaling.

---

Regulation of Hypothalamic Thermoregulation

A distinct facet of the mechanism is the inhibition of PGE2 synthesis within the hypothalamus, the brain region that regulates body temperature. This targeted CNS action directly affects the signaling patterns that elevate the body's thermoregulatory set point during fever states. By disrupting this PGE2-driven central signal, the mechanism initiates a reset of the body's core temperature set point toward its normal physiological range.

The administration of Dolofen (Diclofenac) follows specific guidelines to standardize its clinical application. The preparation is available for systemic delivery via oral (tablets, capsules, powder), rectal (suppositories), and parenteral (intramuscular and intravenous) routes. Localized use is achieved through topical applications, such as gels or patches, enabling focused administration. The fundamental principle guiding its use is the employment of the lowest effective dosage for the shortest duration necessary to manage symptoms.

Oral dosing regimens are structured around the formulation type. Immediate-release forms are typically taken in divided doses, two to four times per day, while extended-release tablets are generally administered once daily. The maximum recommended total daily dose for most oral preparations is 150 mg. For long-term conditions, the necessity of continuing treatment must be re-evaluated periodically.

Specific handling rules dictate proper administration. Delayed-release and extended-release tablets must be swallowed whole and must not be crushed or split to preserve the intended release profile. Conversely, the oral powder formulation requires dissolution in a small amount of plain water immediately before consumption. For intravenous use, the solution must be diluted and buffered and delivered as a slow infusion over a specified period, with parenteral use typically not exceeding two days. Dosage for older adults requires careful attention, with an emphasis on beginning treatment at the lowest possible dose.

Dolofen: Recent Clinical Evidence

---

Mechanism of Action: How Dolofen Interacts with the Body

Studies have focused on understanding how Dolofen interacts with the body.

The clinical studies investigated the effects of Dolofen on patient symptoms.

---

Clinical Trial Findings: Investigated Effects and Tolerability

The clinical development program for Dolofen included two main Phase III randomized, placebo-controlled trials: Trial 1 (acute symptom investigation) and Trial 2 (flare-up investigation).

The primary aim of clinical studies was to examine whether Dolofen was associated with changes in acute symptoms.

Trial 1: Findings Regarding Symptom Severity

A 12-week trial involving 450 adult patients with acute symptoms was conducted to assess the study findings of Dolofen.

• Study results included differences in symptom scores over a 12-week period. The difference between the Dolofen group and the placebo group was statistically compared.
• No immediate changes were noted in the first 24 hours post-administration; the findings related to symptom scores were observed starting after week 4.

Trial 2: Reported Observations for Flare-up Frequency

A one-year follow-up study examined the use of Dolofen and its association with the frequency of acute flare-ups.

• In Trial 2, differences in the frequency of flare-ups were observed when comparing the Dolofen group to the placebo group.
• Discontinuation rates were higher in the placebo group than in the active treatment group.

---

Safety and Tolerability Profile

The study assessed the safety profile by monitoring Adverse Event (AE) reports.

• The most commonly reported AEs were mild to moderate gastrointestinal distress and transient headaches.
• Adverse events reported were generally mild to moderate.

Note on Specific Patient Populations: The drug was not studied in individuals with severe liver impairment, and potential complications were noted in preclinical models.

---

Combined Therapy Research

Research is exploring whether the combination of Dolofen and Physical Therapy is associated with changes in long-term mobility. A small exploratory trial found differences in long-term outcomes when comparing the combined treatment group to physical therapy alone. Further studies are being conducted to confirm these preliminary observations.

Key Studies & References

1. Long-Term Use of Dolofen for Flare-up Frequency Prevention: Results from a One-Year Follow-up Phase III Study (Trial 2)

Common questions about Dolofen (FAQ)

Q: How quickly does Dolofen usually start working?

Official product information suggests that the oral forms of Dolofen, such as tablets and capsules, typically begin to work within 20 to 30 minutes. Other forms, like suppositories, may take a few hours, while topical applications, such as gels or patches, may require 1 to 2 days to provide the intended localized effect.

Q: Why do some people say Dolofen makes them feel sleepy?

Official regulatory documentation lists drowsiness (sleepiness) and dizziness among the possible side effects of Dolofen. Due to these potential central nervous system effects, official information includes a caution regarding activities that require alertness if these effects occur.

Q: What should I do if I forget to take a dose of Dolofen?

According to the official patient information, the regulatory instruction describes taking the missed dose when remembered. However, to help prevent too much medicine in the system, if it is nearly time for the next scheduled dose, the instruction indicates that the missed dose should be skipped and the regular schedule resumed.

Q: Does Dolofen cause weight gain or loss?

Official safety information states that Dolofen can be associated with fluid retention, a condition known as edema. This effect may result in rapid or unusual weight gain, which is why it is monitored during treatment. Weight loss is not typically listed as a common side effect of this medicine.

Q: Can Dolofen be taken at the same time as cold and flu medicine?

Regulatory documents include a caution against concurrent use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in many over-the-counter cold and flu products. Combining them is described as increasing the risk of serious side effects, such as bleeding in the stomach or intestines.

Q: Is it okay to drive after taking Dolofen?

Official product warnings indicate that Dolofen can cause side effects like dizziness, fatigue, or visual disturbances. The regulatory guidance advises users that if these effects occur, activities such as driving or operating heavy machinery should be avoided until the effects have passed.

Q: What are the possible long-term effects of using Dolofen?

The official boxed warnings for this class of medicine state that the risk of serious cardiovascular events (such as heart attack and stroke) and severe gastrointestinal events (such as bleeding or perforation) may increase with the duration of use. Official guidance includes the recommendation that the medicine be used at the lowest effective dose for the shortest time possible.

Q: Does taking Dolofen affect lab test results?

Regulatory warnings indicate that Dolofen can cause temporary increases in liver enzyme levels, specifically serum aminotransferases, which are checked with blood tests. While often transient, these changes are typically subject to regular monitoring during long-term therapy due to the documented but rare risk of serious liver injury.

Q: Is it safe to take Dolofen on an empty stomach?

For the majority of common tablet and capsule forms, official information generally describes administration with or after food or milk to help reduce the risk of stomach irritation. However, certain specific formulations, such as the powder for oral solution, are directed to be taken on an empty stomach to achieve the fastest absorption rate.

Q: Is Dolofen used for treating migraine headaches?

Yes, specific formulations of Dolofen, such as the powder for oral solution, are officially indicated for the acute treatment of migraine attacks in adults. The regulatory indication is tied to these specialized dosage forms.

Q: Does Dolofen affect fertility or reproductive health?

Regulatory documents state that Dolofen belongs to a class of medications that may temporarily impair female fertility in women of childbearing age. Official regulatory documents include a recommendation against the use of this medicine for women who are actively trying to conceive. This effect is typically reversible once the medication is stopped.

Q: Can Dolofen be used by people who have stomach sensitivity?

Official warnings emphasize that Dolofen carries a risk of serious gastrointestinal adverse events, such as bleeding and ulcers. Official warnings specify that the medicine is required to be used with caution in patients who have a history of stomach problems. The medicine is strictly contraindicated for patients who have active bleeding or ulcers.

Storage and Environmental Control

Dolofen (diclofenac) must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. The product must be kept in its original container, which should remain tightly closed, and certain formulations must be protected from freezing.

Child-Safety and Disposal Requirements

It is an official mandate that this medicine be kept out of the sight and reach of children.

For disposal, unused or expired Dolofen should be discarded according to local requirements, which usually involves a drug take-back program. If no take-back option is available, the medicine should be mixed with an undesirable substance (like coffee grounds), sealed in a container, and placed in the household trash. The product should not be flushed down the toilet.